

Jane E Churpek

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1436334/publications.pdf>

Version: 2024-02-01

28
papers

1,884
citations

394421

19
h-index

610901

24
g-index

28
all docs

28
docs citations

28
times ranked

3243
citing authors

#	ARTICLE	IF	CITATIONS
1	Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy. <i>Nature Genetics</i> , 2015, 47, 180-185.	21.4	299
2	Validation and Implementation of Targeted Capture and Sequencing for the Detection of Actionable Mutation, Copy Number Variation, and Gene Rearrangement in Clinical Cancer Specimens. <i>Journal of Molecular Diagnostics</i> , 2014, 16, 56-67.	2.8	234
3	Genomic analysis of germ line and somatic variants in familial myelodysplasia/acute myeloid leukemia. <i>Blood</i> , 2015, 126, 2484-2490.	1.4	207
4	Novel germ line DDX41 mutations define families with a lower age of MDS/AML onset and lymphoid malignancies. <i>Blood</i> , 2016, 127, 1017-1023.	1.4	179
5	Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 9008-9013.	7.1	108
6	Distinct genetic pathways define pre-malignant versus compensatory clonal hematopoiesis in Shwachman-Diamond syndrome. <i>Nature Communications</i> , 2021, 12, 1334.	12.8	103
7	Proposal for the clinical detection and management of patients and their family members with familial myelodysplastic syndrome/acute leukemia predisposition syndromes. <i>Leukemia and Lymphoma</i> , 2013, 54, 28-35.	1.3	88
8	Prognostic tumor sequencing panels frequently identify germ line variants associated with hereditary hematopoietic malignancies. <i>Blood Advances</i> , 2018, 2, 146-150.	5.2	83
9	Development of a tiered and binned genetic counseling model for informed consent in the era of multiplex testing for cancer susceptibility. <i>Genetics in Medicine</i> , 2015, 17, 485-492.	2.4	79
10	Evaluation of Patients and Families With Concern for Predispositions to Hematologic Malignancies Within the Hereditary Hematologic Malignancy Clinic (HHMC). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 417-428.e2.	0.4	74
11	The evolving challenge of therapy-related myeloid neoplasms. <i>Best Practice and Research in Clinical Haematology</i> , 2013, 26, 309-317.	1.7	71
12	Universal genetic testing for inherited susceptibility in children and adults with myelodysplastic syndrome and acute myeloid leukemia: are we there yet?. <i>Leukemia</i> , 2018, 32, 1482-1492.	7.2	48
13	Transcription factor mutations as a cause of familial myeloid neoplasms. <i>Journal of Clinical Investigation</i> , 2019, 129, 476-488.	8.2	47
14	Medical and Surgical Care of Patients With Mesothelioma and Their Relatives Carrying Germline BAP1 Mutations. <i>Journal of Thoracic Oncology</i> , 2022, 17, 873-889.	1.1	44
15	Identifying Inherited and Acquired Genetic Factors Involved in Poor Stem Cell Mobilization and Donor-Derived Malignancy. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 2100-2103.	2.0	42
16	Brca1 deficiency causes bone marrow failure and spontaneous hematologic malignancies in mice. <i>Blood</i> , 2016, 127, 310-313.	1.4	39
17	Recognition of familial myeloid neoplasia in adults. <i>Seminars in Hematology</i> , 2017, 54, 60-68.	3.4	37
18	Approach to the diagnosis of aplastic anemia. <i>Blood Advances</i> , 2021, 5, 2660-2671.	5.2	31

#	ARTICLE	IF	CITATIONS
19	Old and new tools in the clinical diagnosis of inherited bone marrow failure syndromes. Hematology American Society of Hematology Education Program, 2017, 2017, 79-87.	2.5	29
20	Glucocorticoid receptor expression is associated with inferior overall survival independent of BRCA mutation status in ovarian cancer. International Journal of Gynecological Cancer, 2019, 29, 357-364.	2.5	15
21	Feasibility and limitations of cultured skin fibroblasts for germline genetic testing in hematologic disorders. Human Mutation, 2022, 43, 950-962.	2.5	15
22	Heritability of Hematologic Malignancies: From Pedigrees to Genomics. Hematology/Oncology Clinics of North America, 2010, 24, 939-972.	2.2	9
23	Assessing the Feasibility and Limitations of Cultured Skin Fibroblasts for Germline Genetic Testing in Hematologic Disorders. Blood, 2020, 136, 35-36.	1.4	2
24	Spontaneous Hepatic Rupture Associated With Epstein-Barr Virus Negative Aggressive Natural Killer Cell Leukemia. World Journal of Oncology, 2014, 5, 210-213.	1.5	1
25	Targeting Bone Marrow Lymphoid Niches In Acute Lymphoblastic Leukemia. Blood, 2013, 122, 1398-1398.	1.4	0
26	Development of a Data Portal for Aggregation and Analysis of Genomics Data in Familial Platelet Disorder with Predisposition to Myeloid Malignancy - the RUNX1.DB. Blood, 2018, 132, 5241-5241.	1.4	0
27	Final Results from a Phase I Trial Combining Selinexor with High-Dose Cytarabine (HiDAC) and Mitoxantrone (Mito) for Remission Induction in Acute Myeloid Leukemia (AML). Blood, 2018, 132, 4073-4073.	1.4	0
28	A Case of Isolated Myeloid Sarcoma Associated With Germline <i>EGFR</i> T790M Variant: The Importance of Recognizing Potential Germline Variants on Somatic Tumor Sequencing Panels. Journal of Hematology (Brossard, Quebec), 2022, 11, 71-76.	1.0	0